TACIT THERAPEUTICS, INC.

Biotech · Private

RNA editing therapeutic for Dravet syndrome that corrects defective SCN1A sequences in inhibitory neurons

Grants
$999K
1 award
Sector median: 1
Raised
—
No Form D on record
Contracts
—
No federal contracts on record
Patents
20
1 granted · 19 pending
Sector median: 2

Capital Timeline

Federal above the line · equity below · node area scaled to amount
Capital and federal award history
DateEventSourceAmount
Federal grantNational Science Foundation · Phase II · SBIR Phase II: Repurposing RNA processing factors to edit RNA for the treatment of Dravet syndrome$999,255
Federal grant · SBIR/STTR

Peer position

Biotech · 4373 companies · ranked on federal contract value
Biotech companies ranked by federal contract value
#CompanyContractsDisclosed equity
2260Origin Speech Therapy Inc.—$2.6M
2261TRAMPOLINE PHARMA, INC.——
2262HEMATHERIX LLC——
2263TACIT THERAPEUTICS, INC.——
2264SOTERIA SYSTEMS, INC.—$2.7M
2265LineaGen, Inc—$38M
2266GPER G-1 Development Group LLC——

Ranked on federal contract value rather than capital raised. The equity column is the comparison worth making — companies at the same procurement position often sit at very different points in their funding history.

Patents

USPTO · 1 granted of 20
  • Systems And Methods For Promoting Trans-splicingapplication
  • Localization Of Trans-splicing Nucleic Acid Molecules To And Within The Cellular Nucleusapplication
  • Stabilization Of Therapeutic Trans-splicing Rna Molecules In Human Cellsapplication
  • Rna Editing Via Recruitment Of Spliceosome Componentsapplication
  • Rna Editing Via Recruitment Of Spliceosome Componentsgranted
  • High Efficiency Trans-splicing For Replacement Of Targeted Rna Sequences In Human Cellsapplication
  • Trans-splicing System For Tissue-specific Replacement Of Rna Sequencesapplication
  • Rna Editing Via Recruitment Of Spliceosome Componentsapplication
  • Systems And Methods For Promoting Trans-splicingapplication
  • Rna Editing Via Localization Of Trans-splicing Rna Molecules To And Within The Cellular Nucleusapplication
  • Stabilization Of Therapeutic Trans-splicing Rna Molecules In Human Cellsapplication
  • Rna Editing Via Recruitment Of Spliceosome Componentsapplication

Regulatory activity · Biotech

Sector-level, not company-level

Rules are matched to sector, not to company. Recent activity in a sector is context rather than a signal about this business — until rules are matched to what a company actually builds, the section is shown as context and nothing more.